Keyword: Verzenio (abemaciclib)
With oncology head Sue Mahony retiring Friday, Eli Lilly has her replacement ready to step in.
Pfizer breast-cancer fighter Ibrance posted a rare sales miss Tuesday, but it wasn't because Novartis and Lilly are stealing its share.
Lilly Oncology’s marketing chief has some key words for pharma marketers: Don’t lead with data. Put patients’ insights at the forefront instead.
But with six months down and six to go, Humira is on track to keep its pharma TV ad crown for 2018 with spending well ahead of 2017.
Eli Lilly's oncology president Sue Mahony plans to retire at the end of August after 18 years with the drugmaker.
Eli Lilly’s first oncology campaign launched last week, putting the drugmaker on a growing list of pharma companies running DTC ads for cancer drugs.
It’s been only five months since Lilly breast cancer drug Verzenio launched, but it just racked up its third approval in a competitive market.
Trailing in the wake of Pfizer’s Ibrance, Novartis’ Kisqali is one step closer to nabbing a regulatory boost.
With more than 2,000 early retirements settled, Eli Lilly says it's "on track" to hit its goal of cutting 3,500 jobs by year's end.
Lilly's new cancer drug Verzenio faces two tough rivals—Pfizer's Ibrance and Novartis' Kisquali—but the company says it's standing out from the crowd.